Definium Therapeutics (NASDAQ:DFTX) Trading Down 6.2% - Time to Sell?

Key Points

• Definium Therapeutics shares fell 6.2% to $42.34, with trading volume down 73% from the average. Despite the decline, analysts maintain a consensus “Buy” rating and a $55 price target.
• The company reported a quarterly loss of $1.44 per share, missing the consensus estimate of a $0.55 loss by $0.89; analysts expect a full-year loss of approximately $2.27 per share.
• Insiders sold 48,096 shares worth $2.17 million over the past 90 days, while institutional investors own 27.91% of the stock. Definium is developing MM120 and DT402 as treatments for anxiety, ADHD and autism-related conditions.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report)'s stock price was down 6.2% on Tuesday . The company traded as low as $41.81 and last traded at $42.34. Approximately 600,915 shares traded hands during trading, a decline of 73% from the average session volume of 2,245,691 shares. The stock had previously closed at $45.15.

Analyst Upgrades and Downgrades

DFTX has been the topic of several research reports. Oppenheimer set a $60.00 price target on shares of Definium Therapeutics and gave the stock an "outperform" rating in a research report on Monday, June 22nd. Citigroup reiterated a "buy" rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an "outperform" rating in a report on Monday, June 22nd. Piper Sandler reiterated an "overweight" rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research note on Friday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Definium Therapeutics has a consensus rating of "Buy" and a consensus price target of $55.00.

Definium Therapeutics Trading Down 8.7%

The company has a market cap of $4.11 billion, a price-to-earnings ratio of -12.01 and a beta of 2.23. The company's fifty day moving average is $38.32 and its two-hundred day moving average is $26.16. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, research analysts anticipate that Definium Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Activity

In other news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company's stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider owned 174,633 shares of the company's stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 48,096 shares of company stock worth $2,165,763 over the last 90 days. Company insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds have recently bought and sold shares of DFTX. Russell Investments Group Ltd. increased its position in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after acquiring an additional 3,020 shares during the period. Caxton Associates LLP purchased a new stake in Definium Therapeutics in the 3rd quarter worth $126,000. Mercer Global Advisors Inc. ADV increased its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Scientech Research LLC acquired a new position in Definium Therapeutics during the third quarter worth $286,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source